Clinical trials: Recurrent Hepatocellular Cancer
Hepatitis C, Chronic
Low-dose Peg-interferon Plus Ribavirin (IFN/RBV) for Prevention of Hepatocellular Carcinoma (HCC) Recurrence in Patients Who Had Surgery to Remove Primary HCC
The purpose of this study is to determine whether low-dose peg-interferon plus ribavirin therapy is effective in the prevention of hepatocellular carcinoma (HCC) in patients who had the curative resection of primary HCC.
- Trial name
- NCT00375661
- Testing
- interferon-alfa-2b and ribavirin
- Where
- 2 sites in Japan
- Volunteers
- 100 people
- Sponsor
- Kyoto University
HER2-positive Advanced Solid Tumor
A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1303/BNT323 in subjects with advanced solid tumors that express HER2.
- Trial name
- NCT05150691
- Testing
- DB-1303/BNT323, Pertuzumab Injection, Ritonavir
- Where
- 102 sites in United States, Australia and 4 more
- Volunteers
- 796 people
- Sponsor
- DualityBio Inc.
Advanced Adult Primary Liver Cancer, Anaplastic Thyroid Cancer
Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu
Interleukin-12 may kill tumor cells by stopping blood flow to the tumor and by stimulating a person's white blood cells to kill cancer cells.
- Conditions
- Advanced Adult Primary Liver Cancer, Anaplastic Thyroid Cancer, Bone Metastases, Carcinoma of the Appendix
- Trial name
- NCT00004074
- Testing
- recombinant interleukin-12, ABI-007/carboplatin/trastuzumab
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Esophageal Squamous Cell Carcinoma, Advanced Renal Cell Carcinoma
Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program
This phase II trial compares the impact of subcutaneous (SC) nivolumab given in an in-home setting to an in-clinic setting on cancer care and quality of life.
- Conditions
- Advanced Esophageal Squamous Cell Carcinoma, Advanced Renal Cell Carcinoma, Clinical Stage II Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage IIB Cutaneous Melanoma AJCC v8
- Trial name
- NCT06265285
- Testing
- Home Health Encounter, Nivolumab, Patient Monitoring
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Mayo Clinic
Hepatocellular Carcinoma
Prospective Randomized Trial of Laparoscopic Versus Open Liver Resection for HCC
Short-term outcomes of laparoscopic liver resection is better than those of open liver resection Laparoscopic liver resection is better than open resection in immunological aspects
- Trial name
- HCC (NCT00606385)
- Testing
- Liver resection
- Where
- South Korea
- Volunteers
- 84 people
- Sponsor
- Seoul National University Hospital
Breast Cancer, Colorectal Cancer
Cyclophosphamide, Radiation Therapy, and Poly ICLC in Treating Patients With Unresectable, Recurrent, Primary, or Metastatic Liver Cancer
RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Breast Cancer, Colorectal Cancer, Gastric Cancer, Liver Cancer
- Trial name
- NCT00553683
- Testing
- cyclophosphamide, poly ICLC, hepatic artery embolization
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Rutgers, The State University of New Jersey
Hepatocellular Carcinoma
Pembrolizumab as Neoadjuvant Treatment in HCC
The aim of this study is to elucidate the utility of the immune checkpoint inhibitor pembrolizumab in preventing the recurrence of HCC when administered before and after curative surgery or ablation.
- Trial name
- NCT03337841
- Testing
- Pembrolizumab
- Volunteers
- 50 people
- Sponsor
- Kindai University
Hepatocellular Carcinoma
The Impact on Recurrence Risk of Adjuvant Lenvatinib for Patients With Hepatocellular Carcinoma And Microvascular Invasion (MVI) After Hepatectomy : A Random, Controlled, Stage III Clinical Trial.
To compare The Impact on Recurrence Risk of Adjuvant Lenvatinib for Patients With Hepatocellular Carcinoma And Microvascular Invasion (MVI) After Hepatectomy.
- Trial name
- NCT04053972
- Testing
- Lenvatinib
- Where
- China
- Volunteers
- 377 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma, Liver Transplant; Complications
Impact of Graft Reconditioning With Hypothermic Machine Perfusion on HCC Recurrence After Liver Transplantation
The use of devices for liver grafts perfusion before transplantation, either hypothermic (HOPE) or normothermic (NMP), is rapidly spreading thanks to the promising results obtained so far in terms of graft survival and…
- Trial name
- NCT06236568
- Testing
- D-HOPE machine perfusion, Liver transplantation
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- Azienda Ospedaliero-Universitaria di Modena
Liver Cancer
Arsenic Trioxide in Treating Patients With Metastatic Liver Cancer That Cannot Be Removed by Surgery
RATIONALE: Drugs used in chemotherapy, such as arsenic trioxide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00128596
- Testing
- arsenic trioxide
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Pittsburgh
Hepatocellular Carcinoma (HCC)
Safety and Efficacy of Metabolically Armed GPC3 CAR-T Cells Injection (Meta10-GPC3) in Patients With Unresectable Recurrent/Metastatic Hepatocellular Carcinoma
A Study of Metabolically Armed GPC3 CAR-T Cells Injection (Meta10-GPC3) in Patients with Unresectable Recurrent/Metastatic Hepatocellular Carcinoma.
- Trial name
- NCT07487402
- Testing
- Metabolically Armed GPC3 CAR-T cells
- Where
- China
- Volunteers
- 27 people
- Sponsor
- Zhejiang University
Hepatocellular Carcinoma, Hepatitis C, Chronic
Recurrence Rate of Hepatocellular Carcinoma After Treatment of Chronic Hepatits C Patients With Direct Acting Antivirals: Randomized Controlled Phase 3 Trial
Unexpected results were published in 2016 showed increased aggressiveness and rates of HCC recurrence after curative treatment of HCC in HCV patients treated by DAAs achieving SVR.
- Trial name
- CAUTIOUS (NCT03551444)
- Testing
- Administration of DAA-based treatment
- Where
- Egypt
- Volunteers
- 80 people
- Sponsor
- Ain Shams University
Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer
Sunitinib Malate and Capecitabine in Treating Patients With Unresectable or Metastatic Liver Cancer
This phase II trial studies how well giving sunitinib malate together with capecitabine works in treating patients with unresectable or metastatic liver cancer.
- Conditions
- Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer
- Trial name
- NCT00787787
- Testing
- sunitinib malate, capecitabine
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- University of Washington
Ischemic Reperfusion Injury, Liver Injury
Recurrence of Liver Malignancy After Ischemia/Reperfusion Injury
Severe ischemic changes of the liver remnant after hepatectomy could expedite tumor recurrence on the residual liver. Our study aimed at assessing the effect of warm ischemic/reperfusion (I/R) injuries on surgery-to-local…
- Conditions
- Ischemic Reperfusion Injury, Liver Injury, Cancer Recurrence, Malignancy
- Trial name
- annie-liver (NCT04257240)
- Testing
- selective hepatic vascular exclusion, semielective hepatic vascular exclusion
- Volunteers
- 230 people
- Sponsor
- Aretaieion University Hospital
Hepatocellular Carcinoma, Recurrence
Sorafenib Treatment in Patients With Hepatocellular Carcinoma With Microvascular Invasion After Radical Resection
This prospective multicenter non-randomized controlled study evaluates the efficacy and safety of treatment with Sorafenib (Nevaxar) in patients with hepatocellular carcinoma with microvascular invasion after radical resection…
- Trial name
- NCT02867280
- Testing
- Sorafenib
- Where
- China
- Volunteers
- 154 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma
Multimodal Ultrasound and Hepatocellular Response to Local Treatments
Consecutive patients with HCC who should undergo to locoregional treatments (ablation or trans-arterial chemoembolization) according to international guidelines will be enrolled.
- Trial name
- NCT05987514
- Testing
- multimodal ultrasound
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Hepatocellular Carcinoma, RFA
Radiofrequency Ablation Combined With Transcatheter Arterial Chemoembolization Versus Radiofrequency Ablation Alone for Recurrent Hepatocellular Carcinoma
The combination of transcatheter arterial chemoembolization (TACE) with RFA has also reported to be an effective treatment for HCC.
- Conditions
- Hepatocellular Carcinoma, RFA, TACE
- Trial name
- NCT01415063
- Testing
- RFA, TACE-RFA
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma, Hepatitis C Virus Infection
Treatment With IFN After Curative Resection of HCC in HCV-Related Cirrhosis
We conducted a randomized controlled trial of adjuvant interferon (IFN) therapy in patients with hepatitis-C virus (HCV)-related cirrhosis who underwent curative resection of hepatocellular carcinoma (HCC) to investigate whether…
- Conditions
- Hepatocellular Carcinoma, Hepatitis C Virus Infection, Liver Cirrhosis, Interferon Treatment
- Trial name
- NCT00273247
- Testing
- Interferon alpha-2b
- Where
- Italy
- Volunteers
- 150 people
- Sponsor
- National Cancer Institute, Milan
Neoplasms
A Study of the Safety and Effects of ADH-1 Given Intravenously as a Single Agent
N-cadherin, a protein involved in blood vessel cell binding, is increased as cancer progresses, and is on the surface of many tumor cells. ADH-1 blocks N-cadherin.
- Trial name
- NCT00264433
- Testing
- ADH -1 (Exherin™)
- Where
- 11 sites in United States, Canada
- Sponsor
- Adherex Technologies, Inc.
BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma
Yttrium Y 90 Glass Microspheres, Atezolizumab, and Cabozantinib for the Treatment of Unresectable or Locally Advanced Hepatocellular Carcinoma
This phase II trial tests whether yttrium Y 90 glass microspheres, atezolizumab, and cabozantinib work to shrink tumors in patients with liver cancer (hepatocellular carcinoma) that cannot be removed by surgery (unresectable) or…
- Conditions
- BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma, Locally Advanced Hepatocellular Carcinoma, Recurrent Hepatocellular Carcinoma
- Trial name
- NCT05327738
- Testing
- Atezolizumab, Biopsy, Cabozantinib S-malate
- Sponsor
- OHSU Knight Cancer Institute